EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Biomarker Testing Rates and Patterns in Patients With Metastatic Non–Small Cell Lung Cancer: A Prospective, Observational Study in Community Practices

Makenzi Evangelist, Bo Wang, James E Butrynski, John Paschold, Patrick J Ward iD, David M Waterhouse iD, Robert M Jotte, Kashif Ali iD, Donald A Richards, Kartik Konduri, Anton Melnyk, Rami S Owera und 8 weitere

JCO Precision Oncology · 2026-04 · 10 (4)

DOI: 10.1200/po-25-00832 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift JCO Precision Oncology, 2026-04. Verfasst von Makenzi Evangelist und 19 weiteren Autor:innen. Beteiligte Einrichtung: New York Oncology Hematology, Albany, NY. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE As targeted therapies are associated with improved outcomes in patients with non–small cell lung cancer (NSCLC) with genetic alterations, biomarker testing is recommended to identify actionable alterations (AAs). Here, we report findings on biomarker testing in the subset of patients with metastatic (m)NSCLC from the Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Consortium Protocol 2 study. METHODS In this prospective, noninterventional, observational study, patients 18 years and older with NSCLC (excluding stage IA) were enrolled from 18 community practices in the United States from 2020 to 2022 (ClinicalTrials.gov identifier: NCT05644808 ). Biomarker testing rates relative to timing of first-line (1L) therapy initiation, testing modalities, AAs, 1L therapies, next-generation sequencing (NGS) characteristics, and survival outcomes were examined. In addition, testing rates were compared with our previous retrospective analysis (Protocol 1). RESULTS Among 556 patients with mNSCLC, 98.8% received testing for ≥1 biomarker at any time and 79.0% received ≥1 test result before initiating 1L therapy (versus 89.9% and 79.2%, respectively, in Protocol 1 [2018-2020]); 72.8% and 55.6% of patients received NGS testing and NGS results before 1L therapy, respectively (versus 37.0% and 5.0%, respectively, in Protocol 1); 63.5% and 44.1% of patients received guideline-compliant (8-gene) testing and 8-gene test results, respectively, before 1L therapy. Among patients who received biomarker test results before 1L therapy and had an AA (n = 94), 77.7% (n = 73) received 1L-targeted therapy. Survival outcomes trended favorably in these patients. CONCLUSION Although guideline-compliant (8-gene) and NGS testing rates fall short of recommended guidelines, several improvements in testing rates from Protocol 1 were observed. In addition, almost 80% of patients, who received test results before 1L therapy and had an AA, received 1L targeted therapy. Improved survival outcomes in these patients highlight the importance of effective follow-through from testing to treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsBiomarkers, TumorHumansProspective StudiesFemaleMaleAgedMiddle AgedNeoplasm Metastasis

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • New York Oncology Hematology, Albany, NY.
  • Sarah Cannon Research Institute, Nashville, TN.
  • Willamette Valley Cancer Institute and Research Center, Eugene, OR.
  • Virginia Oncology Associates, Norfolk, VA.
  • Oncology Hematology Care, Inc, Cincinnati, OH.
  • Rocky Mountain Cancer Centers, Lone Tree, CO.

ORCID-Profile: Patrick J Ward, David M Waterhouse, Kashif Ali, Eric M Lander, Nicholas J Robert, David R Spigel, Melissa L Johnson

Zitieren

APA

Evangelist, M., Wang, B., Butrynski, J. E., Paschold, J., Ward, P. J., Waterhouse, D. M., Jotte, R. M., Ali, K., Richards, D. A., Konduri, K., Melnyk, A., Owera, R. S., Hakimian, D., Ghaddar, H., Lander, E. M., Robert, N. J., Yori, J. L., Upadhyay, V., Spigel, D. R., & Johnson, M. L. (2026). Biomarker Testing Rates and Patterns in Patients With Metastatic Non–Small Cell Lung Cancer: A Prospective, Observational Study in Community Practices. JCO Precision Oncology, 10(4). https://doi.org/10.1200/po-25-00832

Vancouver

Evangelist M, Wang B, Butrynski JE, Paschold J, Ward PJ, Waterhouse DM, et al. Biomarker Testing Rates and Patterns in Patients With Metastatic Non–Small Cell Lung Cancer: A Prospective, Observational Study in Community Practices. JCO Precision Oncology. 2026;10(4). doi:10.1200/po-25-00832

BibTeX
@article{Evangelist2026,
  author = {Evangelist, Makenzi and Wang, Bo and Butrynski, James E and Paschold, John and Ward, Patrick J and Waterhouse, David M and Jotte, Robert M and Ali, Kashif and Richards, Donald A and Konduri, Kartik and Melnyk, Anton and Owera, Rami S and Hakimian, David and Ghaddar, Habib and Lander, Eric M and Robert, Nicholas J and Yori, Jennifer L and Upadhyay, Vikalp and Spigel, David R and Johnson, Melissa L},
  title = {Biomarker Testing Rates and Patterns in Patients With Metastatic Non–Small Cell Lung Cancer: A Prospective, Observational Study in Community Practices},
  journal = {JCO Precision Oncology},
  year = {2026},
  volume = {10},
  number = {4},
  doi = {10.1200/po-25-00832}
}
Kostenlos starten →